检索结果：
返回 147 结果。
排序：
期刊
- 作者：
Huai-liang Wu ，Wen Xia ，Zhengyang Xu ，Hanxing Zhou ，Limin Chen ，Yongkui Lu ，Xinlan Liu ，Danmei Pang ，Yan Liu ，Qianyi Lu ，Fei Xu ，Xin An ，Jiajia Huang ，Kuikui Jiang ，Jingmin Zhang ，Yili Cai ，Ruoxi Hong ，Qiufan Zheng ，null ，Shusen Wang （ 1Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China;2Chemoradiotherapy Center of Oncology, The affiliated people’s hospital of Ningbo University, Ningbo, China;3Department of Medical Oncology, The affiliated seventh hospital of Sun Yat-sen University, Shenzhen, China;4Department of Breast, Bone & Soft Tissue Oncology, Guangxi Medical University Cancer Hospital, Nanning, China;5Department of Oncology, Ningxia Medical University General Hospital, Yinchuan, China;6Department of Breast Oncology, The First People’s Hospital of Foshan, Foshan, China ） - 出处： Signal Transduction and Targeted Therapy 2026 Vol.11
- 摘要： Treatment options for patients with hormone receptor -positive, human epidermal growth factor receptor 2 -negative advanced breast cancer that progre
- 作者：
厚玉瑾 ，刘新兰 ，王金 ，赵艳姣 ，张海霞 ，田稼 ，郭婷 ，王南 ，孙海涛 - 关键词： 奥沙利铂化疗 线粒体凋亡 内质网应激 化疗敏感性 胃癌细胞
- 摘要： 课题组早期研究中发现RASSF6基因和蛋白在胃癌细胞中低表达,且低表达与胃癌分化程度、肿瘤浸润深度、淋巴结转移、胃癌分期有关。RASSF6过表达可抑制胃癌细胞增殖、迁移,促进凋亡。本研究认为RASSF6表达可抑制细胞增殖且促进凋亡,相关机制如下：RASSF6抑制MAPK通路及AKT信号途径,从而抑制
期刊
- 作者：
Guoshuang Shen ，Zhilin Liu ，Miaozhou Wang ，Yi Zhao ，Xinlan Liu ，Yujin Hou ，Wenbiao Ma ，Jingqi Han ，Xiaofeng Zhou ，Dengfeng Ren ，Fuxing Zhao ，Zitao Li ，Shifen Huang ，Yongzhi Chen ，Yingjian He ，Yan Liu ，Zij （ Breast Disease Diagnosis and Treatment Center,Affiliated Hospital of Qinghai University,Affiliated Cancer Hospital of Qinghai University,Xining,China；Medical Oncology Department of General Hospital of Ningxia Medical University,Yinchuan,China;( ） - 出处： 信号转导与靶向治疗（英文版) 2025 第10卷 第3期 P1578-1586
- 摘要： We aimed to evaluate the efficacy and safety of adding apatinib,to sintilimab and chemotherapy in the neoadjuvant treatment of early triple-negative b
期刊
- 作者：
Huimin Lv ，Tao Sun ，Xiaoling Ling ，Xinlan Liu ，Jin Yang ，Mengwei Zhang ，Limin Niu ，Shumin Chen ，Zhenzhen Liu ，Chengzheng Wang ，Huihui Sun ，Jing Wang ，Huiai Zeng ，Shengnan Zhao ，Lanwei Guo ，Yajing Feng ，Zhiqing Zhang ，Qingxin Xia ，Rongguo Qiu & …Min Yan （ 1Department of Breast Disease, Henan Breast Cancer Center, the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China;2Breast Medicine, Cancer Hospital of China Medical University, Liaoning Cancer Hospital, Liaoning, China;3The First Hospital of Lanzhou University, Lanzhou, China;4Departments of Oncology, General Hospital of Ningxia Medical University, Yinchuan, China;5Department of Medical Oncology, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China;6Department of Clinical Research Management, the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China;7Department of Pathology, the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China;8Beijing Biostar Pharmaceuticals Co., Ltd., Beijing, China ） - 出处： BMC Medicine 2026 Vol.24 No.1
- 关键词： Anti-HER2 therapy Immune checkpoint inhibitors Chemotherapy HER2-positive Advanced breast cancer
- 摘要： Background The efficacy and safety of anti-HER2 therapy and immune checkpoint inhibitors combined with chemotherapy to treat HER2-positive advanced b
期刊
- 作者：
Shen Guoshuang ，Liu Zhilin ，Wang Miaozhou ，Zhao Yi ，Liu Xinlan ，Hou Yujin ，Ma Wenbiao ，Han Jingqi ，Zhou Xiaofeng ，Ren Dengfeng ，Zhao Fuxing ，Li Zitao ，Huang Shifen ，Chen Yongzhi ，He Yingjian ，Liu Yan ，Zhu Zijun ，Li Yongxin ，Li Jinming ，Da Mengting ，Mo Hongnan ，Du Feng ，Cui Liang ，Bai Jing ，Liu Zhen ，Ma Fei ，Zhao Jiuda （ Affiliated Hospital of Qinghai University；Medical Oncology Department of General Hospital of Ningxia Medical University；Peking University Cancer Hospital & Institute；Medical College of Qinghai University；National Cancer Center/Cancer Hospital；Peking University Cancer Hospital and Institute；Geneplus-Beijing Institute ） - 出处： 信号转导和靶向治疗 2025 第10卷 第3期 P1578-1586
- 摘要： We aimed to evaluate the efficacy and safety of adding apatinib, to sintilimab and chemotherapy in the neoadjuvant treatment of early triple-negative
期刊
- 作者：
Huan Yang ，Qu-Chang Ouyang ，Min Yan ，Xiao-Jia Wang ，Xi-Chun Hu ，Ze-Fei Jiang ，Tao Huang ，Zhong-Sheng Tong ，Shu-Sen Wang ，Yong-Mei Yin ，Hui Li ，Run-Xiang Yang ，Hua-Wei Yang ，Yue-E Teng ，Tao Sun ，Li Cai ，Hong-Yuan Li ，Xue-Nong Ouyang ，Jian-Jun He ，Xin-Lan Liu ，Shun-E Yang ，Jin-Hu Fan ，Jia-Yu Wang ，You-Lin Qiao ，Bing-He Xu （ Department of Cancer Epidemiology，National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital，Chinese Academy of Medical Sciences and Peking Union Medical College，Beijing，China；Department of Breast Cancer Medical Oncology，Hunan Cancer Hospital，Changsha，China；Department of Breast Disease，Henan Breast Cancer Center，The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital，Zhengzhou，China；Department of Medical Oncology，Zhejiang Cancer Hospital，Hangzhou，China；Department of Medical Oncology，Fudan University Shanghai Cancer Center，Shanghai，China；Department of Breast Cancer，The Fifth Medical Center of Chinese People’s Liberation Army General Hospital，Beijing，China；Department of Breast and Thyroid Surgery，Union Hospital，Tongji Medical College，Huazhong University of Science and Technology，Wuhan，China；Department of Breast Oncology，Key Laboratory of Breast Cancer Prevention and Therapy，National Clinical Research Center for Cancer，Tianjin Medical University Cancer Institute and Hospital，Tianjin，China；Department of Medical Oncology，State Key Laboratory of Oncology in South China，Sun Yat-sen University Cancer Center，Guangzhou，China；Department of Medical Oncology，The First Affiliated Hospital of Nanjing Medical University，Nanjing，China；Department of Breast Surgery，Sichuan Province Tumor Hospital，Chengdu，China；Department of Medical Oncology，Yunnan Cancer Hospital，Kunming Medical University，Kunming，China；Department of Breast Surgery，The Affiliated Tumor Hospital of Guangxi Medical University，Nanning，China；Departments of Medical Oncology and Thoracic Surgery，The First Hospital of China Medical University，Shenyang，China；Department of Medical Oncology，Cancer Hospital of China Medical University，Liaoning Cancer Hospital and Institute，Key Laboratory of Liaoning Breast Cancer Research，Shenyang，China；The Fourth Department of Internal Medical Oncology，Harbin Medical University Cancer Hospital，Harbin，China；Department of the Endocrine and Breast Surgery，The First Affiliated Hospital of Chongqing Medical University，Chongqing Medical University，Chongqing，China；Department of Medicine Oncology，900 Hospital of the Joint Logistics Team，Fuzhou，China；Department of Breast Surgery，The First Affiliated Hospital of Xi’an Jiaotong University，Xi’an，China；Department of Oncology，General Hospital of Ningxia Medical University，Yinchuan，China；Department of Breast Cancer and Lymphoma，Affiliated Tumor Hospital of Xinjiang Medical University，Urumqi，China；Department of Cancer Epidemiology，National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital，Chinese Academy of Medical Sciences and Peking Union Medical College，Beijing，China；Department of Medical Oncology，National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital，Chinese Academy of Medical Sciences and Peking Union Medical College，Beijing，China；Department of Cancer Epidemiology，National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital，Chinese Academy of Medical Sciences and Peking Union Medical College，Beijing，China；Department of Medical Oncology，National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital，Chinese Academy of Medical Sciences and Peking Union Medical College，Beijing，China ） - 出处： 转化医学年鉴 2022 第10卷 第15期 P813
- 关键词： Age at initial diagnosis breast cancer clinicopathological characteristics treatment prognosis
- 摘要： Background Several studies have indicated possible associations between age and the prognosis of breast cancer , but limited data are available from h
期刊
- 作者：
Hong, Ruo-Xi ，Xu, Fei ，Xia, Wen ，Teng, Yue-E ，Ouyang, Qu-Chang ，Zheng, Qiu-Fan ，Yuan, Zhong-Yu ，Chen, Dong-Shao ，Jiang, Kui-Kui ，Lin, Ying ，Dai, Zhen ，Liu, Xin-Lan ，Chen, Qian-Jun ，Wu, Xin-Hong ，Shi, Yan-Xia ，Huang, Jia-Jia ，An, Xin ，Xue, Cong ，Bi, Xi-Wen ，Chen, Mei-Ting ，Li, Hui ，Yao, He-Rui ，Zou, Guo-Rong ，Huang, Heng ，Zhang, Jing-Min ，Wang, Shu-Sen （ aDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China;bDepartment of Breast Internal Medicine, The First Hospital of China Medical University, Shenyang, China;cDepartment of Breast Cancer Medical Oncology, Hunan Cancer Hospital, Changsha, China;dBreast Disease Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China;eChengdu Center for Disease Control and Prevention, Chengdu, China;fDepartment of Medical Oncology, General Hospital of Ningxia Medical University, Yinchuan, China;gDepartment of Breast, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China;hDepartment of Breast Cancer, Hubei Cancer Hospital, Wuhan, China;iDepartment of Breast Surgery, Sichuan Cancer Hospital, Chengdu, China;jBreast Tumor Centre, Department of Medical Oncology, Phase I Clinical Trial Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China;kDepartment of Oncology, Panyu District Cancer Institute, Panyu Central Hospital, Guangzhou, China;lDepartment of Breast Surgery, Lianjiang People’s Hospital, Lianjiang, China ） - 出处： Journal of Clinical Oncology 2025 Vol.43 No.11 P1314-1324
- 摘要： PURPOSE The effects of metronomic chemotherapy plus endocrine therapy have yet to be elucidated through a randomized phase III clinical trial. METHODS
期刊
- 作者：
Binghe Xu ，Qingyuan Zhang ，Yang Luo ，Zhongsheng Tong ，Tao Sun ，Changping Shan ，Xinlan Liu ，Yumin Yao ，Bing Zhao ，Shusen Wang ，Xiaohua Zeng ，Changlu Hu ，Xi Yan ，Xiaojia Wang ，Hongyan Jia ，Zhendong Chen ，Fuming Qiu ，Xinhong Wu ，Deyong Zhang ，null ，Tong Li （ 1National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China;2Harbin Medical University Cancer Hospital, Harbin, China;3Tianjin Medical University Cancer Institute and Hospital, Tianjin, China;4Cancer Hospital of China Medical University, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital and Institute, Shenyang, China;5The Affiliated Hospital of Jining Medical University, Jining, China;6General Hospital of Ningxia Medical University, Yinchuan, China;7Liaocheng People’s Hospital, Liaocheng, China;8Cancer Hospital of Xinjiang Medical University, Urumuqi, China;9Sun Yat-sen University Cancer Center, Guangzhou, China;10Breast Cancer Center, Affiliated Cancer Hospital of Chongqing University, Chongqing, China;11Anhui Provincial Cancer Hospital, Hefei, China;12West China Hospital, Sichuan University, Chengdu, China;13Cancer Hospital of the University of Chinese Academy of Sciences/Zhejiang Cancer Hospital, Institute of Cancer and Basic Medicine, Chinese Academy of Sciences, Hangzhou, China;14The First Hospital of Shanxi Medical University, Taiyuan, China;15The Second Affiliated Hospital of Anhui Medical University, Hefei, China;16The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China;17Hubei Cancer Hospital, Wuhan, China;18Genor Biopharma Co., Ltd, Beijing, China ） - 出处： Nature Communications 2025 Vol.16
- 摘要： Lerociclib , a highly selective oral CDK4/6 inhibitor, has displayed anti-tumor activity and differentiated safety and tolerability profile in previou
期刊
- 作者：
Yuanfang Xin ，Guoxin Zhang ，Qiuxia Dong ，Yaobang Liu ，Xingfa Huo ，Yumei Guan ，Yonghui Zheng ，Qianqian Fang ，Dengfeng Ren ，Fuxing Zhao ，Zitao Li ，Xinlan Liu ，Jiuda Zhao （ Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University，Xining，Qinghai 810000，China；The Second Ward of Oncology，Qinghai Red Cross Hospital，Xining，Qinghai 810000，China；Department of Medical Oncology，General Hospital of Ningxia Medical University，Yinchuan，Ningxia 750000，China；The Second Ward of Oncology，Qinghai Red Cross Hospital，Xining，Qinghai 810000，China；Department of Surgical Oncology，General Hospital of Ningxia Medical University，Yinchuan，Ningxia 750000，China；Precision Medicine Center of Oncology，The Affiliated Hospital of Qingdao University，Qingdao，Shandong 266035，China；Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University，Xining，Qinghai 810000，China；Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University，Xining，Qinghai 810000，China；Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University，Xining，Qinghai 810000，China；Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University，Xining，Qinghai 810000，China；Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University，Xining，Qinghai 810000，China；Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University，Xining，Qinghai 810000，China；Department of Medical Oncology，General Hospital of Ningxia Medical University，Yinchuan，Ningxia 750000，China；Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University，Xining，Qinghai 810000，China ） - 出处： 癌症发生与治疗(英文) 2025 第3卷 第2期 P154-162
- 关键词： Breast cancer Lung metastasis Nomogram Prognosis Surveillance Survival prediction model
- 摘要： Background: Breast cancer is the most diagnosed cancer worldwide, and patients' survival decreases with metastasis. We conducted a retrospective stud
期刊
- 作者：
Guoshuang Shen ，Zhilin Liu ，Miaozhou Wang ，Yi Zhao ，Xinlan Liu ，Yujin Hou ，Wenbiao Ma ，Jingqi Han ，Xiaofeng Zhou ，Dengfeng Ren ，Fuxing Zhao ，Zitao Li ，Shifen Huang ，Yongzhi Chen ，Yingjian He ，Yan Liu ，Zijun Zhu ，Yongxin Li ，Jinming Li ，Mengting Da ，Hongnan Mo ，Feng Du ，Liang Cui ，Jing Bai ，Zhen Liu ，Fei Ma ，Jiuda Zhao （ 1Breast Disease Diagnosis and Treatment Center, Affiliated Hospital of Qinghai University, Affiliated Cancer Hospital of Qinghai University;2Medical Oncology Department of General Hospital of Ningxia Medical University;3Department of Oncology, 2nd Ward, Qinghai Provincial People’s Hospital (Breast and Thyroid Surgery);4Department of pathology, Affiliated Hospital of Qinghai University, Affiliated Cancer Hospital of Qinghai University;5Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Breast Center, Peking University Cancer Hospital & Institute;6Department of Public Health, Medical College of Qinghai University;7State Key Laboratory of Molecular Oncology, Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College;8Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing),The VIPII Gastrointestinal Cancer Division of Medical Department, Peking University Cancer Hospital and Institute, 52 Fucheng Rd, Haidian District;9Geneplus-Beijing Institute ） - 出处： Signal Transduction and Targeted Therapy 2025 Vol.10 No.1 P1-9
- 摘要： We aimed to evaluate the efficacy and safety of adding apatinib, to sintilimab and chemotherapy in the neoadjuvant treatment of early triple-negative